|
Index prescription drug
|
Total number of patients (a + b)
|
Number of patients with no B/T filled/administered within 3 months, n (%) (a)
|
Number of patients with ≥1 B/T filled/administered within 3 months, n (%) (b)
|
First B/T filled/administered after index that was different from the index prescription (among b)
|
|---|
|
Anti-TNF biologics
|
|
Adalimumab (SC)
|
118
|
56
|
(47.5)
|
62
|
(52.5)
|
10 etanercept
|
|
Certolizumab (SC)
|
11
|
6
|
(54.5)
|
5
|
(45.5)
|
1 certolizumab IV
|
|
Etanercept (SC)
|
202
|
65
|
(32.2)
|
137
|
(67.8)
|
1 adalimumab
|
|
Golimumab (SC)
|
17
|
8
|
(47.1)
|
9
|
(52.9)
|
None
|
|
Golimumab (IV)
|
1
|
–
| |
1
|
(100.0)
|
None
|
|
Infliximab (IV)
|
28
|
14
|
(50.0)
|
14
|
(50.0)
|
None
|
|
Non-anti-TNF biologics
|
|
Abatacept (IV)
|
23
|
8
|
(34.8)
|
15
|
(65.2)
|
5 abatacept SC
|
|
Abatacept (SC)
|
9
|
5
|
(55.6)
|
4
|
(44.4)
|
None
|
|
Anakinra (SC)
|
1
|
–
| |
1
|
(100.0)
|
None
|
|
Rituximab (IV)
|
7
|
4
|
(57.1)
|
3
|
(42.9)
|
1 abatacept SC
|
|
Tocilizumab (IV)
|
2
|
1
|
(50.0)
|
1
|
(50.0)
|
None
|
|
Tocilizumab (SC)
|
1
|
1
|
(100.0)
|
–
| |
–
|
|
New synthetic DMARD
|
|
Tofacitinib (oral)
|
14
|
8
|
(57.1)
|
6
|
(42.9)
|
None
|
|
Total
|
434
|
176
|
(40.6)
|
258
|
(59.4)
|
18 discrepancies
|
- B/T biologics/tofacitinib, TNF tumor necrosis factor, SC subcutaneous, IV intravenous infusion, DMARD disease-modifying anti-rheumatic drug
